Overview
Full-Life Technologies Limited is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. The company develops radiopharmaceuticals by attaching radionuclides to targeting vectors (peptides, small molecules, and single domain antibodies) to deliver payloads directly to tumors. Their radiotechnology platform covers production and logistics of radiopharmaceutical drug products.
Key people
In the news
- A new milestone for c-MET-targeted radioconjugate therapy Full-Life Technologies is pleased to announce the U.S. FDA IND clearance and Australian regulatory clearance of [²²⁵Ac]Ac-FL-261, our potentially first-in-class c-MET-targeted alpha radioconjugate. 🎯 Targeting c-MET in solid tumors FL-261 is being developed for multiple solid tumor indications, with an initial focus on non-squamous non-small cell lung cancer (nsNSCLC), and is designed to selectively target c-MET-expressing tumors. ⚛️ Precision alpha delivery By combining
- Another important milestone for Full-Life Technologies! 🏭 Construction of our manufacturing facility in Gembloux, Belgium, is now complete, and accelerator commissioning and initial ramp-up are underway. ⚛️ One step closer to establishing our in-house radioisotope production capabilities. #FullLifeTechnologies #Radiopharmaceuticals #Actinium225
- Join Full-Life Technologies at EANM’26 in Vienna and ESMO 2026 in Madrid this October. We’re excited to share new clinical and translational progress across our radiopharmaceutical pipelines, including updates from FL-261 and [²²⁵Ac]Ac-FL-020. 📍 EANM’26 | Vienna | Oct 17–21 📍 ESMO 2026 | Madrid | Oct 23–27 We look forward to connecting with colleagues and partners across the nuclear medicine and oncology communities. See the slide for presentation and booth details. #EANM26 #ESMO2026 #FullLifeTechnologies
Something wrong or missing? Send an update. Fixed within 24 hours.